[
  {
    "ts": "2025-05-19T17:01:00+00:00",
    "headline": "Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System",
    "summary": "Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain relief1. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two core competencies",
    "url": "https://finance.yahoo.com/news/stryker-receives-fda-clearance-optablate-170100337.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "1f1ec6b1-1ad2-3117-8248-6365cbf074ac",
      "content": {
        "id": "1f1ec6b1-1ad2-3117-8248-6365cbf074ac",
        "contentType": "STORY",
        "title": "Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System",
        "description": "",
        "summary": "Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain relief1. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two core competencies",
        "pubDate": "2025-05-19T17:01:00Z",
        "displayTime": "2025-05-19T17:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/2f8ba181d79b7befb0f75c6e86d8a09f",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "OptaBlate BVN ablation in vertebral body",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QY68MsFDM8BdHq9_1SWg2A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2f8ba181d79b7befb0f75c6e86d8a09f.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rdk0vHSbE3k9EXMxuNRFVw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2f8ba181d79b7befb0f75c6e86d8a09f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stryker-receives-fda-clearance-optablate-170100337.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stryker-receives-fda-clearance-optablate-170100337.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SYK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]